Related Experiment Video

Updated: Mar 26, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.1K

[Mechanisms of Resistance in Antihormone Therapies of Advanced Prostate Cancer]

P Thelen1, J Gschwend2, J-M Wolff3

  • 1Urologische Klinik und Poliklinik, Universitätsmedizin Göttingen.

Aktuelle Urologie
|January 28, 2016
PubMed

Insights

New prostate cancer drugs Abiraterone and Enzalutamide offer options beyond Docetaxel. Understanding their distinct resistance mechanisms is crucial for effective sequencing and overcoming treatment failure in castration-resistant prostate cancer.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Docetaxel, Abiraterone, and Enzalutamide are first-line treatments for castration-resistant prostate cancer.
  • Treatment resistance and failure are inevitable with current therapies.
  • Cross-resistance diminishes the efficacy of second-line treatments.

Purpose of the Study:

  • To investigate the distinct mechanisms of resistance to Abiraterone and Enzalutamide.
  • To provide clinical validation for preclinical findings on resistance pathways.
  • To inform optimal sequencing strategies for these agents in prostate cancer treatment.

Main Methods:

  • Analysis of clinical data to confirm resistance mechanisms.
  • Comparative study of treatment outcomes based on drug sequencing.
  • Exploration of molecular pathways involved in treatment failure.

Main Results:

  • Preclinical data suggest differing resistance mechanisms for Abiraterone and Enzalutamide.
  • Clinical evidence is needed to confirm these distinct pathways.
  • Understanding these differences may guide personalized treatment selection.

Conclusions:

  • Distinct resistance mechanisms for Abiraterone and Enzalutamide exist.
  • Clinical confirmation is essential for optimizing treatment sequencing.
  • Future strategies may involve tailored drug combinations or sequences based on resistance profiles.

More Related Videos

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
6.2K